Watch FTH. Know when insiders buy.
One email the day a filing lands. Free.
FTH
Faeth Therapeutics, Inc.
35.37
−3.72 −9.52%
USD · close Sep 15
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $914MP/E —DIV YIELD —FCF YIELD -3.70%REV TTM —NET INCOME −$195.5MNET CASH $26.3M52W 7.89 – 40.05SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$18.4M | −$16M | — | -2.84 | −$15.7M | $0 | −$15.7M | Aug 4 |
| Q1 2026 · Mar 31 | — | — | — | −$170.6M | −$170.2M | — | -131.45 | −$10.7M | $6K | −$10.7M | Aug 4 |
| Q4 2025 · Dec 31derived | — | — | — | −$5M | −$4.7M | — | -3.74 | −$3.9M | $0 | −$3.9M | Mar 30 |
| Q3 2025 · Sep 30 | — | — | — | −$4.9M | −$4.6M | — | -3.62 | −$3.6M | $0 | −$3.6M | Nov 14 |
| Q2 2025 · Jun 30 | — | — | — | −$5.2M | −$4.9M | — | -3.91 | −$5.9M | $16K | −$5.9M | Aug 4 |
| Q1 2025 · Mar 31 | — | — | — | −$7.3M | −$6.9M | — | -5.45 | −$7.1M | $0 | −$7.1M | Aug 4 |
| Q4 2024 · Dec 31derived | — | — | — | −$8.3M | −$7.8M | — | -6.17 | −$5.8M | $0 | −$5.8M | Mar 30 |
| Q3 2024 · Sep 30 | — | — | — | −$7.8M | −$7.3M | — | -5.77 | −$5.5M | $0 | −$5.5M | Nov 14 |
| Q2 2024 · Jun 30 | — | — | — | −$7.8M | −$7.1M | — | -5.69 | −$5.8M | $109K | −$5.9M | Nov 14 |
| Q1 2024 · Mar 31 | — | — | — | −$8.7M | −$8M | — | -0.32 | −$7.6M | $37K | −$7.7M | Nov 14 |
| Q4 2023 · Dec 31derived | — | — | — | −$8.1M | −$7.4M | — | -0.30 | −$6.2M | $0 | −$6.2M | Mar 28 |
| Q3 2023 · Sep 30 | — | — | — | −$7.7M | −$7.1M | — | -0.28 | −$4.7M | $0 | −$4.7M | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$22.3M | −$21.1M | — | -16.72 | −$20.5M | $16K | −$20.5M | — | — |
| FY2024 · to Dec 31 | — | — | −$32.6M | −$30.2M | — | -24.01 | −$24.7M | $146K | −$24.8M | — | — |
| FY2023 · to Dec 31 | — | — | −$37.1M | −$34.1M | — | -1.22 | −$32M | $180K | −$32.2M | $10.4M | — |
| FY2022 · to Dec 31 | — | — | −$50.2M | −$48.6M | — | -1.58 | −$39M | $321K | −$39.3M | — | — |
| FY2021 · to Dec 31 | — | — | −$37.5M | −$36.8M | — | -1.33 | −$30.3M | $2M | −$32.3M | — | — |
| FY2020 · to Dec 31 | — | — | −$19.5M | −$20.1M | — | -12.53 | −$17.7M | $1.2M | −$18.9M | — | — |
Every number comes from Faeth Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.